| Literature DB >> 34770935 |
Zhen-Tao Deng1,2,3, Wen-Yan Li2, Lei Wang2, Zhi-Ping Zhou1,2, Xing-De Wu2,4, Zhong-Tao Ding1, Qin-Shi Zhao2.
Abstract
Catharanthus roseus is a well-known traditional herbal medicine for the treatment of cancer, hypertension, scald, and sore in China. Phytochemical investigation on the twigs and leaves of this species led to the isolation of two new monoterpene indole alkaloids, catharanosines A (1) and B (2), and six known analogues (3-8). Structures of 1 and 2 were established by 1H-, 13C- and 2D-NMR, and HREIMS data. The absolute configuration of 1 was confirmed by single-crystal X-ray diffraction analysis. Compound 2 represented an unprecedented aspidosperma-type alkaloid with a 2-piperidinyl moiety at C-10. Compounds 6-8 exhibited remarkable Cav3.1 low voltage-gated calcium channel (LVGCC) inhibitory activity with IC50 values of 11.83 ± 1.02, 14.3 ± 1.20, and 14.54 ± 0.99 μM, respectively.Entities:
Keywords: Catharanthus roseus; Cav3.1 low voltage-gated calcium channel (LVGCC); catharanosine A; monoterpene indole alkaloid
Mesh:
Substances:
Year: 2021 PMID: 34770935 PMCID: PMC8587030 DOI: 10.3390/molecules26216516
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–8.
1H-NMR (600 MHz) and 13C-NMR (150 MHz) spectroscopic data of compounds 1 and 2 in CDCl3 (δ in ppm, J in Hz).
| No. | 1 | 2 | ||
|---|---|---|---|---|
|
|
|
|
| |
| 2 | 184.4 | 3.71, s | 83.3 | |
| 3 | 3.11, d (8.8) | 62.8 | 3.48, d (13.2) | 50.8 |
| 2.90, d (13.2) | ||||
| 5 | 2.87, dd (6.0, 2.9) | 59.3 | 3.38, m | 51.6 |
| 2.69, m | ||||
| 6 | 2.50, dd (12.8, 6.0) | 44.3 | 2.41, m | 43.6 |
| 1.74, d (12.8) | 2.17, m | |||
| 7 | 57.4 | 52.8 | ||
| 8 | 132.0 | 124.2 | ||
| 9 | 6.76, d (2.4) | 114.9 | 7.36, s | 122.1 |
| 10 | 154.9 | 114.4 | ||
| 11 | 6.59, dd (8.4, 2.4) | 111.8 | 158.0 | |
| 12 | 6.65, d (8.4) | 109.7 | 5.97, s | 92.3 |
| 13 | 135.3 | 153.8 | ||
| 14 | 1.98, m | 28.4 | 5.82, ddd (10.2, 4.9, 1.3) | 124.4 |
| 1.33, m | ||||
| 15 | 2.65, s | 26.1 | 5.18, d (10.2) | 130.0 |
| 16 | 1.78, m | 47.8 | 79.4 | |
| 17 | 3.34, m | 65.0 | 5.34, s | 76.2 |
| 18 | 1.40, d (6.7) | 12.0 | 0.43, t (7.4) | 7.5 |
| 19 | 5.09, q (6.7) | 114.6 | 1.56, m | 30.9 |
| 0.97, m | ||||
| 20 | 135.6 | 42.7 | ||
| 21 | 3.38, s | 48.3 | 2.76, s | 66.5 |
| 22 | 171.8 | |||
| 2′ | 4.29, br s | 54.6 | ||
| 3′ | 2.10, m | 28.7 | ||
| 1.80, m | ||||
| 4′ | 1.92, m | 23.4 | ||
| 1.53, m | ||||
| 5′ | 1.86, m | 22.0 | ||
| 1.66, m | ||||
| 6′ | 3.10, d (11.8) | 45.7 | ||
| 2.83, m | ||||
| N-Me | 2.65, s | 37.9 | ||
| 10-OMe | 3.63, s | 55.7 | ||
| 11-OMe | 3.80, s | 55.7 | ||
| 22-OMe | 3.76, s | 52.3 | ||
| OAc | 170.8 | |||
| 2.03, s | 21.0 | |||
Figure 2Key 1H–1H COSY, HMBC and ROESY correlations of 1.
Figure 3X-ray ORTEP drawing of 1.
Figure 4Key 1H–1H COSY, HMBC and ROESY correlations of 2.
Scheme 1Plausible biosynthesis pathway of 2.
Figure 5Effects of compounds 3–8 on current Cav3.1 low-voltage-gated calcium channel at 50 μM. All the data were represented as mean ± SD (n = 3).
Figure 6Effects of compounds 6–8 and the positive control (mibefradil) on current of Cav3.1. (A–D) Dose-responsive curves of 6-8 and mibefradil on peak current of Cav3.1. Data points represent mean ± SD of three or four repetition measurements. Solid curve represents fit to the Hill equation. (E–H) Representative Cav3.1 peak current traces in the absence and presence of different concentrations of 6–8 and mibefradil. (I–L) Normalized I-V curves of Cav3.1 control (blue), Cav3.1 with 12.5 μM 6–8 (red), 3 μM mibefradil, and washout (black). All the data were represented as mean ± SD (n = 3). (M–P) Current traces obtained with Cav3.1 at various membrane potentials (from −80 to +60 mV in 10 mV increasement at 4 s intervals) from a holding potential of −100 mV (upper panel). Current traces obtained with Cav3.1 with 6–8 (12.5 μM) and mibefradil (3 μM) using same stimulating voltages (lower panel).